Two Sigma Advisers
BTTX

Two Sigma Advisers’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Two Sigma Advisers’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-70,600
Closed -$140K – 2943
2022
Q1 		$140K Buy
70,600
+12,500
+22% +$43.2K ﹤0.01% 2445
2021
Q4 		$270K Buy
+58,100
New +$476K ﹤0.01% 2174

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Two Sigma Advisers's BTTX Position: Q2 2022 in Review

Two Sigma Advisers sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q2 2022, closing a stake of 70,600 shares — an estimated $140K sold.

Two Sigma Advisers first reported a position in BTTX in Q4 2021 and held it in 2 quarters. The position peaked at $270K in Q4 2021. 14 funds tracked by Wall St. Rank hold BTTX as of Q2 2022.

  • Two Sigma Advisers reported no remaining Better Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 70,600 Better Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $140K.
  • Two Sigma Advisers first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Two Sigma Advisers's Better Therapeutics, Inc. Common Stock position peaked at $270K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.